Yahoo · Aug 24, 2026
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says
Immunovant (IMVT) has broad diversification with encouraging updates but faces balanced risk/reward
IM
NASDAQ · IMVT
Immunovant, Inc.
Healthcare · Biotechnology
$38.75
Down-$0.82 (-2.07%)
Updated Sep 10, 2026, 7:52 AM
SID Score
5.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.35B
- P/E ratio
- -9.28
- Dividend yield
- 0.00%
- 52-week range
- $22.79 – $45.42
- Volume
- 1.02M
- Avg. volume
- 1.69M
Price performance
IMVT price history
1M range · 20 trading sessions · Daily adjusted prices
IMVT closed at $38.75 after 20 trading sessions, down 9.04% for the selected period.
- Last close
- $38.75
- Period change
- -9.04%
- Period low
- $38.75
- Period high
- $44.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $39.11 | $39.73 | $38.67 | $38.75 | 1.02M |
| Sep 8, 2026 | $38.59 | $40.5602 | $38.34 | $39.57 | 1.51M |
| Sep 4, 2026 | $39.44 | $39.73 | $38.73 | $39.25 | 765.74K |
| Sep 3, 2026 | $39.48 | $39.48 | $38.64 | $39.12 | 1.24M |
| Sep 2, 2026 | $40.15 | $40.955 | $38.61 | $39.49 | 1.33M |
| Sep 1, 2026 | $40.60 | $41.37 | $39.20 | $39.90 | 1.59M |
| Aug 31, 2026 | $40.96 | $41.28 | $39.91 | $40.82 | 1.39M |
| Aug 28, 2026 | $43.27 | $43.375 | $41.085 | $41.20 | 1.08M |
| Aug 27, 2026 | $43.60 | $43.945 | $43.14 | $43.82 | 868.54K |
| Aug 26, 2026 | $43.54 | $44.21 | $42.645 | $43.89 | 852.46K |
| Aug 25, 2026 | $43.79 | $44.50 | $43.27 | $43.50 | 1.35M |
| Aug 24, 2026 | $44.00 | $44.04 | $43.20 | $43.32 | 1.19M |
| Aug 21, 2026 | $44.85 | $45.121 | $44.08 | $44.37 | 846.6K |
| Aug 20, 2026 | $44.37 | $44.69 | $43.42 | $44.35 | 954.41K |
| Aug 19, 2026 | $45.265 | $45.42 | $44.11 | $44.96 | 1.27M |
| Aug 18, 2026 | $42.95 | $44.38 | $42.64 | $44.30 | 1.54M |
| Aug 17, 2026 | $41.72 | $43.89 | $41.46 | $43.71 | 1.22M |
| Aug 14, 2026 | $42.16 | $42.16 | $40.82 | $41.82 | 722.49K |
| Aug 13, 2026 | $42.92 | $42.92 | $41.63 | $41.82 | 1.36M |
| Aug 12, 2026 | $40.92 | $42.62 | $40.705 | $42.60 | 2M |
Latest IMVT news
The latest Smart Investors Daily articles mentioning IMVT.
Stock researchCompany · Overview
IMVT research
Overview
Company profile and research snapshot.
Company profile
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $16.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | JP Morgan | Overweight | — |
| Jun 30, 2026 | Citigroup | Buy | — |
| May 26, 2026 | Guggenheim | Buy | — |
| May 22, 2026 | Truist Securities | Hold | — |
| May 21, 2026 | B of A Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 13, 2026
Immunovant (IMVT) Q1 2027 Earnings Call Transcript
CEO signals multiple pivotal data readouts ahead as cash runway supports IMVT-1402 development.
SeekingAlpha · Aug 6, 2026
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsConference Call ParticipantsStephanie Lee Griffin - Roivant...
Benzinga · Aug 6, 2026
Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
